An observational study in AMD - Age-Related Macular Degeneration, sponsored by Democritus University of Thrace. Not yet recruiting at 1 site in Greece. Open to participants aged 60 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Democritus University of Thrace · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Macular Degeneration with a site in Greece — 5 open to participants now, 6 under way, 2 of them phase 3. Macular Degeneration · Greece.
Among the 18 studies in Macular Degeneration with a site in Greece, this one is one of 5 that started in 2025, is one of 8 observational ones, and was the 18th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →5 of the 18 studies in Macular Degeneration with a site in Greece are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Greece, Austria, Czechia and 10 more countries
Ages 50+
AbbVie · Sites in Greece, United States, Austria and 14 more countries
Ages 50+
ONL Therapeutics · Sites in Greece, United States, Austria and 9 more countries
Ages 55+
The Foundation for Orthopaedics and Regenerative Medicine · Sites in Greece, United States
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 60 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 111 across 410 observational studies indexed under Macular Degeneration.
Median enrollment 306 across the 10 interventional studies, 316 across the 8 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 10 most frequent:
Democritus University of Thrace is the lead sponsor of 71 studies on the registry; 9 are open to participants now.
Democritus University of Thrace has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
2 of the studies in Macular Degeneration with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060196Democritus University of ThraceThe Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration | 2026-12-31 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Macular Degeneration with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly worldwide. The dry, non-exudative form of the disease, although more common, is associated with gradual and significant decline in functional vision. Despite advancements in diagnostic and therapeutic approaches, a targeted intervention that improves the daily functionality of these patients is still lacking. One critical, yet often overlooked, factor that affects daily performance is lighting conditions.
This study aims to objectively assess the impact of different lighting intensity levels on patients with advanced dry AMD during the execution of everyday activities. A total of 60 individuals will be evaluated (30 healthy controls over 60 years of age and 30 patients with clinically diagnosed advanced AMD, according to NICE and AREDS criteria). Participants will undergo ophthalmological assessment (visual acuity, contrast sensitivity, OCT/OCTA, autofluorescence), and their performance on five functional tasks (mobility, object grasping, sit-to-stand transition, obstacle avoidance, and hanging clothes) will be evaluated under eight lighting levels (20-300 lux) at a constant color temperature (4000K), in a specially designed laboratory equipped with motion and eye-tracking systems.
The primary endpoint is overall performance, based on task completion time and errors, expressed on a custom performance scale (0-100). Secondary data include changes in pupil size as an indicator of visual adaptation. The study aims to determine the optimal lighting range that maximizes functional vision and improves the quality of life for patients with AMD.
Introduction Aging is associated with an increased prevalence of neurodegenerative disorders and leads to irreversible changes in both humans and animal models. The retina, a layer of neural tissue that lines the interior of the eyeball, is exposed to various harmful and stressful environmental factors, including age-related changes, which affect its function. Age-related macular degeneration (AMD) is the leading cause of visual decline and blindness worldwide in individuals aged 65 years and older. The number of patients suffering from AMD is expected to increase significantly in the coming decades. AMD primarily affects the macular region of the retina, which is responsible for central vision. It has a significant impact on patients' lives due to the loss of sharp and color vision, interfering with daily activities such as recognizing faces and reading.
To date, there is no proven treatment that slows or prevents the progression of advanced AMD. Laser photocoagulation and photodynamic therapy reduce the risk of moderate or severe vision loss in some individuals with the neovascular form of the disease. Other medical and surgical interventions are under investigation, but none have been shown to be effective. Identifying the exact pathophysiological mechanisms of AMD remains challenging. However, clinico-pathological observations and epidemiological studies have provided valuable insights into potential pathways involved in AMD development. AMD is generally classified into two forms: non-exudative (dry or atrophic) and exudative (wet).
Exudative AMD is characterized by the development of choroidal neovascularization (CNV), i.e., fibrovascular tissue that grows from the choriocapillaris, penetrates through breaks in Bruch's membrane into the sub-retinal pigment epithelium (RPE) space, and then under the neurosensory retina. Dry AMD involves dysfunction in the RPE-Bruch's membrane-choriocapillaris complex, resulting in lesions such as drusen (small, yellow-white deposits located mainly in the macular area), focal pigment clumping, and RPE atrophy. The most severe atrophic lesion observed in AMD is geographic atrophy, characterized by a well-demarcated round or oval area of depigmentation or clear absence of RPE cells.
The wet form of AMD represents less than 10% of cases but can lead to severe complications if untreated. The latest approach in CNV treatment includes intravitreal injections of anti-angiogenic agents. Vascular Endothelial Growth Factor (VEGF) plays a key role in angiogenesis and in the development of all forms of wet AMD, regardless of angiographic appearance, and increases vascular permeability. Anti-VEGF drugs aim to inhibit VEGF activity, thereby suppressing neovascular growth and reducing vascular leakage. However, this therapy merely delays disease progression. Thus, there is a need for novel preventive and therapeutic strategies targeting AMD.
One factor influencing AMD patients' ability to perform daily activities is lighting conditions. According to current literature, the ideal lighting conditions for AMD patients have not yet been thoroughly studied. Recently, our research team published a pioneering mathematical model to determine optimal lighting intensity in phakic and pseudophakic patients. Identifying optimal lighting for AMD patients could greatly enhance their quality of life.
It is also known that some individuals overestimate or underestimate their functional daily abilities based on self-assessed visual performance using questionnaires. Moreover, visual acuity alone is insufficient to provide a comprehensive assessment of patients' visual capacity. Ideally, any functional impairment should be objectively and realistically evaluated for each patient, either at home or in their work environment, by carefully assessing their performance in specific daily tasks.
Various activities have been developed to assess distance, as well as near and intermediate visual abilities. Mobility has been assessed in individuals with glaucoma using a specific framework of daily activities, and near/intermediate vision tasks have been evaluated in AMD patients. In contrast, performance in individuals with presbyopia and in those who have undergone presbyopia-correcting surgery has been evaluated using a different activity framework under stable or variable lighting conditions to determine optimal illumination levels.
Purpose The aim of this study is to evaluate the performance of patients with advanced-stage dry AMD in daily activities under different lighting conditions.
Method
This is a prospective observational comparative study involving a total of 60 participants, divided into two groups:
Healthy controls over the age of 60
Patients with bilateral diagnosed advanced AMD (according to the UK's National Institute for Health and Care Excellence-NICE-or AREDS 9-step classification), fulfilling at least one of the following criteria:
i) Geographic atrophy of the macula ii) Best-corrected visual acuity in the affected eye \<6/18 or logMAR >0.4 with dense/confluent drusen, advanced RPE changes, or vitelliform lesions iii) Fibrous scar iv) RPE tear v) Atrophy (absence/thinning of RPE and/or retina) vi) Cystoid degeneration (persistent intraretinal fluid or tubular structures unresponsive to therapy)
All participants will undergo a clinical evaluation at the Ophthalmology Outpatient Clinic and the Gait Analysis Laboratory of the University General Hospital of Evros. Initial assessments will include best-corrected monocular visual acuity using the validated DDiVAT chart and contrast sensitivity using the Pelli-Robson chart. Diagnostic evaluations will include macular optical coherence tomography (OCT), OCT angiography (OCT-A), and fundus autofluorescence imaging for AMD staging. All examinations will be conducted in accordance with standard clinical practice, without any interventional medical procedures.
Following clinical evaluation, participants will perform five daily activities under eight different lighting intensities (20, 50, 100, 125, 150, 200, 250, and 300 lux), with fixed light temperature (4000K). The performance will be assessed at the Gait Analysis Laboratory, which features a custom lighting setup of four adjustable light fixtures, installed based on a professional lighting design study.
The lab is equipped with an infrared motion-detection camera system, which, through special body-mounted reflectors, captures full-body movement, task duration, and motion fluidity in real time.
Additionally, the setup includes eye-tracking glasses, capable of measuring pupil size, blink rate, and saccadic eye movements. All devices are controlled by integrated software that extracts the data mentioned above. This system will be used to evaluate patients' performance in daily tasks under each lighting condition.
Daily Activities
Mobility: Patients walk a set distance along a corridor with grey obstacles at their self-selected pace.
Reach and grasp tasks: A white table is divided into 9 sections. Three small (24 mm), three medium (55 mm), and three large (73 mm) objects are randomly placed. Participants are asked to locate a specific object and place it on a marked black cross at a designated spot.
Sit-to-stand and stand-to-sit: Patients transition between two chairs placed opposite each other, repeating the sequence three times as fast as possible.
Overhead obstacle avoidance: Patients pass under a stretched rope placed at 1.5 m height.
Clothesline task: Patients pick up four differently colored garments from a basket and hang them on a fixed clothesline using clothespins.
Primary Outcome Activity Scores: Each participant's activity score will be calculated based on task completion time and errors. Errors will incur time penalties. A total completion time will be derived for each activity under each lighting condition. A custom scoring scale from 0 (lowest) to 100 (highest) will be developed. Each participant's performance score will be generated from this scale, determining the optimal lighting condition for AMD patients.
Secondary Outcome Pupil Size: The behavior of patients' pupil sizes under different lighting conditions will be assessed to correlate pupil response with light intensity.
Statistical Analysis An a priori power analysis was conducted. For an effect size of 0.17 of the activity score, 26 participants will be required in each study group to achieve a power of 0.8 at a significance level of 0.05. The normality of measurement data will be assessed using the Shapiro-Wilk test. Normally distributed data will be analyzed with the t-test. Non-normally distributed data will be analyzed with the Mann-Whitney U test. p-values \< 0.05 will be considered statistically significant. All statistical analyses will be performed using the Medcalc statistical software (Medcalc Software, Mariakerke, Belgium).
Patients with bilateral diagnosed advanced AMD (according to the UK's National Institute for Health and Care Excellence-NICE-or AREDS 9-step classification [13]), fulfilling at least one of the following criteria:
i) Geographic atrophy of the macula ii) Best-corrected visual acuity in the affected eye \<6/18 or logMAR >0.4 with dense/confluent drusen, advanced RPE changes, or vitelliform lesions iii) Fibrous scar iv) RPE tear v) Atrophy (absence/thinning of RPE and/or retina) vi) Cystoid degeneration (persistent intraretinal fluid or tubular structures unresponsive to therapy)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy controls
Diagnostic Test: Distant Visual Acuity · Diagnostic Test: Optical Coherence Tomography · Diagnostic Test: Optical Coherence Tomography Angiography
Patients with AMD stage 9 in both eyes.
Diagnostic Test: Distant Visual Acuity · Diagnostic Test: Optical Coherence Tomography · Diagnostic Test: Optical Coherence Tomography Angiography · Diagnostic Test: Autofluorescence imaging
Distant Visual acuity of all participants using DDART web-application monocularly in both eyes.
Optical Coherence Tomography of the macula will be performed to all patients.
Optical Coherence Tomography Angiography of the macula will be performed to all patients.
Autofluorescence imaging using fundus camera for AMD staging.
ADL score
Each participant's activity score will be calculated based on task completion time and errors. Errors will incur time penalties. A total completion time will be derived for each activity under each lighting condition. A custom scoring scale from 0 (lowest) to 100 (highest) will be developed. Each participant's performance score will be generated from this scale, determining the optimal lighting condition for AMD patients.
Time frame: On the same day as clinical evaluation, approximately 2-4 hours following baseline assessments.
Pupil Size
The behavior of patients' pupil sizes under different lighting conditions will be assessed to correlate pupil response with light intensity.
Time frame: On the same day as clinical evaluation, approximately 2-4 hours following baseline assessments.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.
Of 108 non-industry observational studies under Macular Degeneration, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 98. This study's planned 18 months is below that.
Counting every sponsor, half of 164 studies reached it within 44 months; a quarter within 15 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Democritus University of Thrace